SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy. With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
DitchCarbon Score
How does SK Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK Biopharmaceuticals's score of 34 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 12,882,000 kg CO2e, comprising 433,000 kg CO2e from Scope 1, 1,046,000 kg CO2e from Scope 2, and 11,882,000 kg CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 emissions from 425,000 kg CO2e in 2022, while Scope 2 emissions rose from 936,000 kg CO2e. The total emissions for 2022 were about 6,547,000 kg CO2e for Scope 3, indicating a significant increase in this category as well. SK Biopharmaceuticals has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they have consistently reported their emissions across all relevant scopes, demonstrating transparency in their sustainability efforts. The company is headquartered in South Korea (KR) and operates within the biopharmaceutical industry, which is increasingly focusing on reducing carbon footprints and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 328,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 841,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SK Biopharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
